<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="60449">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01978535</url>
  </required_header>
  <id_info>
    <org_study_id>12-009963</org_study_id>
    <nct_id>NCT01978535</nct_id>
  </id_info>
  <brief_title>Iron Sucrose in Adolescents With Iron Deficiency and Postural Orthostatic Tachycardia Syndrome (POTS)</brief_title>
  <official_title>A Randomized, Controlled, Double Blinded Clinical Trial of Intravenous Iron Sucrose in Adolescents With Non-anemic Iron Deficiency and Postural Orthostatic Tachycardia Syndrome (POTS)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mayo Clinic</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Mayo Clinic</source>
  <oversight_info>
    <authority>United States: Institutional Review Board</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is designed to investigate whether the treatment of non-anemic iron deficiency
      with intervenous iron sucrose will result in decreased symptom reporting and improved
      cardiovascular indices in adolescents (age 12-18) with Postural Orthostatic Tachycardia
      Syndrome (POTS).
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>October 2013</start_date>
  <completion_date type="Anticipated">July 2015</completion_date>
  <primary_completion_date type="Anticipated">January 2015</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Cardiovascular indices-Intraval change in heart rate during 10-minute head up tilt table test</measure>
    <time_frame>7 (+/- 2) days following intervention</time_frame>
    <safety_issue>No</safety_issue>
    <description>This study will assess whether a single infusion of iron sucrose will improve cardiovascular indices, specifically a reduction in the intraval of measured heart rate change, during a ten minute head up tilt, in adolescent subjects with POTS and non-anemic iron deficiency</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Postural Orthostatic Tachycardia Syndrome</condition>
  <arm_group>
    <arm_group_label>Iron infusion</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Iron Sucrose (Venofer (R))</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Normal saline infusion</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Equal volume to intervention of normal saline</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Iron infusion</intervention_name>
    <description>5 mg/kg of intravenous iron sucrose supplied as Venofer (TM) with a maximum dose of 200mg.  Iron sucrose will be diluted to 1 mg of elemental iron in 1 mL of NaCl 0.9% with a maximum volume of 210 mL.</description>
    <arm_group_label>Iron infusion</arm_group_label>
    <other_name>Iron sucrose</other_name>
    <other_name>Venofer (TM)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Normal saline infusion</intervention_name>
    <description>Normal saline (NaCl 0.9%) 5 mL/kg up to a maximum volume 210 mL</description>
    <arm_group_label>Normal saline infusion</arm_group_label>
    <other_name>Normal saline</other_name>
    <other_name>NaCl 0.9%</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria

          -  aged 12-18 years

          -  chronic (&gt;3 months)symptoms of orthostatic intolerance (including but not limited to
             lightheadedness, syncope, headache, fatigue, weakness, sweating, nausea and
             palpitations)

          -  symptomatic orthostatic heart rate increase of greater than or equal to 40 beats per
             minute during a 10 minute 70 degree head up tilt study

          -  presence of non-anemic iron deficiency, defined as serum ferritin level less than or
             equal to 12 ug/L with normal hemoglobin

        Exclusion criteria

          -  orthostatic hypotension within 3 minutes of 70 degree head up tilt

          -  pregnant or lactating females

          -  presence of other organ failure or systemic illness that can affect autonomic
             function

          -  concurrent medication therapy with anticholinergic, alpha-adrenergic antagonists,
             beta-adrenergic antagonists unless medication is held for five half-lives prior to
             study

          -  laboratory evidence of anemia or iron overload

          -  personal history of hematochromatosis or first degree relative with hematochromatosis

          -  known sensitivity to Venofer (TM) or other intravenous iron preparations
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>18 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Amie Jones, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mayo Clinic</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Mayo Clinic in Rochester</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tonette Gehrking</last_name>
      <phone>507-284-4462</phone>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2014</verification_date>
  <lastchanged_date>May 30, 2014</lastchanged_date>
  <firstreceived_date>June 7, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Mayo Clinic</investigator_affiliation>
    <investigator_full_name>Amie E. Jones, M.D.</investigator_full_name>
    <investigator_title>PI</investigator_title>
  </responsible_party>
  <keyword>POTS</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Tachycardia</mesh_term>
    <mesh_term>Anemia, Iron-Deficiency</mesh_term>
    <mesh_term>Postural Orthostatic Tachycardia Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Ferric oxide, saccharated</mesh_term>
    <mesh_term>Ferric Compounds</mesh_term>
    <mesh_term>Iron</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
